Cancer in Puerto Rico

IARC estimates 16,568 new cancer cases and 7,876 cancer deaths in Puerto Rico in 2024; the commonest new cancers are prostate, colorectum and breast. This page is assembled automatically from OnCo's data: 234 trials with a site there, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

16,568

all cancers

Deaths

7,876

all cancers

Incidence rate

236.1

per 100,000, age-standardised

Mortality rate

99.9

per 100,000, age-standardised

Cumulative risk

23.8%

of a cancer by age 74

Population

3,242,208

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Prostate	2,789	79.5	Prostate cancer
Colorectum	2,259	29.2	Colorectal cancer
Breast	2,182	61.6	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Thyroid	1,033	22.8	Thyroid cancer
Trachea, bronchus and lung	897	9.7	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Non-Hodgkin lymphoma	734	10.3	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Corpus uteri	720	22.2	Endometrial cancer
Bladder	543	5.2	Bladder & urothelial cancer
Leukaemia	541	8.6	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Liver and intrahepatic bile ducts	496	5.6	Hepatocellular carcinoma

Most deaths

Site	Deaths	Rate	OnCo page
Colorectum	1,116	13.7	Colorectal cancer
Trachea, bronchus and lung	765	8.3	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Prostate	690	19.8	Prostate cancer
Breast	674	18.0	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Liver and intrahepatic bile ducts	461	5.3	Hepatocellular carcinoma
Pancreas	459	5.1	Pancreatic ductal adenocarcinoma
Leukaemia	380	5.8	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Non-Hodgkin lymphoma	359	4.6	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Bladder	307	2.9	Bladder & urothelial cancer
Stomach	252	2.6	Gastric & gastro-oesophageal junction cancer

Incidence: method 1, trends in national rates projected to 2024.
Mortality: method 3c, national incidence estimates applied to model-based mortality-to-incidence ratios (registry survival data).
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Puerto Rico”, in Caribbean (Latin America and the Caribbean), high income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

234 trials in OnCo · 93 recruiting overall

234 trials

Trial			Lead sponsor
Durvalumab with chemotherapy in high-risk early breast cancer NCT06058377	Phase 3	Recruiting	National Cancer Institute (NCI)	561	2026-10-09
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer NCT07659782	Phase 2	Recruiting	Verastem, Inc.	19	2026-10-07
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, NCT06820463	Phase 2	Recruiting	AbbVie	75	2026-10-07
AHOD2131 (COG / NCTN) NCT05675410	Phase 3	Recruiting	National Cancer Institute (NCI)	417	2026-10-07
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a NCT04858334	Phase 2	Recruiting	National Cancer Institute (NCI)	455	2026-10-07
ComboMATCH (EAY191) NCT05564377	Platform trial	Recruiting	National Cancer Institute (NCI)	483	2026-10-07
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb NCT03486873	Phase 3	Recruiting	Merck Sharp & Dohme LLC	782	2026-10-07
myeloMATCH NCT05564390	Platform trial	Recruiting	National Cancer Institute (NCI)	355	2026-10-07
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer NCT05827081	Phase 3	Recruiting	Novartis Pharmaceuticals	229	2026-10-07
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer NCT06790693	Phase 3	Recruiting	Hoffmann-La Roche	242	2026-10-06
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650	Phase 3	Recruiting	Merck Sharp & Dohme LLC	330	2026-10-06
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176	Phase 3	Recruiting	Merck Sharp & Dohme LLC	259	2026-10-06
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan NCT06952504	Phase 3	Recruiting	Merck Sharp & Dohme LLC	265	2026-10-06
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma NCT06084936	Phase 3	Recruiting	Hoffmann-La Roche	83	2026-10-06
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer NCT07228832	Phase 3	Recruiting	Summit Therapeutics	236	2026-10-06
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) NCT06136624	Phase 3	Recruiting	Merck Sharp & Dohme LLC	288	2026-10-06
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metast NCT07775287	Phase 3	Recruiting	Genmab	4	2026-10-06
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorecta NCT07702032	Phase 3	Recruiting	Genmab	8	2026-10-06
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer NCT07166094	Phase 3	Recruiting	Genmab	177	2026-10-06
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). NCT05947851	Phase 3	Recruiting	Merck Sharp & Dohme LLC	84	2026-10-05
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) NCT07723248	Phase 3	Recruiting	ORIC Pharmaceuticals	12	2026-10-05
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations NCT06772623	Phase 1/2	Recruiting	AbbVie	124	2026-10-05
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re NCT05519085	Phase 3	Recruiting	Celgene	266	2026-09-30
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) NCT06079671	Phase 3	Recruiting	AstraZeneca	205	2026-09-30
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations NCT06581432	Phase 2	Recruiting	Boehringer Ingelheim	92	2026-09-29
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL NCT05952024	Phase 2	Recruiting	AstraZeneca	57	2026-09-29
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) NCT06881784	Phase 3	Recruiting	Revolution Medicines, Inc.	158	2026-09-29
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors NCT06943755	Phase 2/3	Recruiting	Exelixis	131	2026-09-29
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT06973187	Phase 3	Recruiting	BeOne Medicines	217	2026-09-28
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac NCT06742996	Phase 3	Recruiting	BeOne Medicines	150	2026-09-28

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Puerto Rico, captured 2026-10-07 to 2026-10-10. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Puerto Rico is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

OnCo holds no institution, company or person in Puerto Rico.

Approvals

OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Puerto Rico is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Puerto Rico's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Puerto Rico, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines regulator, its approval routes and its decisions.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Puerto Rico's own sources.

Puerto Rico is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/pr.json; every country: /api/v1/countries.json.